Genomic Health, Inc. (NASDAQ:GHDX) CEO Kimberly J. Popovits sold 25,000 shares of the firm’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $73.85, for a total value of $1,846,250.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Kimberly J. Popovits also recently made the following trade(s):
- On Friday, August 9th, Kimberly J. Popovits sold 50,000 shares of Genomic Health stock. The shares were sold at an average price of $73.76, for a total value of $3,688,000.00.
GHDX stock traded down $0.31 during trading hours on Monday, hitting $73.12. 423,743 shares of the stock traded hands, compared to its average volume of 580,289. The firm has a 50-day moving average of $62.79. Genomic Health, Inc. has a one year low of $50.77 and a one year high of $92.18. The firm has a market capitalization of $2.73 billion, a P/E ratio of 69.64 and a beta of 1.06. The company has a current ratio of 5.74, a quick ratio of 5.67 and a debt-to-equity ratio of 0.17.
Several large investors have recently added to or reduced their stakes in GHDX. Renaissance Technologies LLC boosted its position in shares of Genomic Health by 18.3% in the 2nd quarter. Renaissance Technologies LLC now owns 2,814,500 shares of the medical research company’s stock valued at $163,719,000 after purchasing an additional 435,000 shares during the period. Norges Bank acquired a new position in shares of Genomic Health in the 4th quarter valued at $20,975,000. Fiera Capital Corp acquired a new position in shares of Genomic Health in the 1st quarter valued at $20,134,000. FMR LLC boosted its position in shares of Genomic Health by 83.8% in the 4th quarter. FMR LLC now owns 550,627 shares of the medical research company’s stock valued at $35,466,000 after purchasing an additional 251,085 shares during the period. Finally, Assenagon Asset Management S.A. boosted its position in shares of Genomic Health by 269.2% in the 1st quarter. Assenagon Asset Management S.A. now owns 267,410 shares of the medical research company’s stock valued at $18,732,000 after purchasing an additional 194,988 shares during the period. Institutional investors and hedge funds own 95.15% of the company’s stock.
Several research analysts recently weighed in on GHDX shares. Deutsche Bank decreased their target price on Genomic Health from $80.00 to $55.00 and set a “hold” rating for the company in a research note on Thursday, May 30th. Canaccord Genuity cut Genomic Health from a “buy” rating to a “hold” rating and decreased their target price for the company from $77.00 to $72.00 in a research note on Tuesday, July 30th. Barclays raised Genomic Health from an “underweight” rating to an “equal weight” rating and raised their target price for the company from $45.00 to $72.00 in a research note on Tuesday, July 30th. Zacks Investment Research raised Genomic Health from a “hold” rating to a “buy” rating and set a $77.00 target price for the company in a research note on Wednesday, July 31st. Finally, ValuEngine raised Genomic Health from a “hold” rating to a “buy” rating in a research note on Saturday, July 27th. Nine investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Genomic Health presently has an average rating of “Hold” and an average price target of $69.86.
About Genomic Health
Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.
Featured Story: Is the Dow Jones Industrial Average (DJIA) still relevant?
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.